New research has found a novel target with therapeutic potential for metastatic eye melanoma—an aggressive eye cancer—with ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The discovery may explain why cutting edge CAR T-cell therapy has managed to revolutionized treatment for blood cancer but ...

Biomodal reports methylation sequencing is expanding the window for early detection.

Lung cancer cases are on the rise in non-smokers around the world, and air pollution could be an insidious, contributing ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

Researchers have uncovered new patterns of DNA damage associated with specific chemotherapy drugs to guide cancer treatment for less effects.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Molecular profiling could reduce both overtreatment and undertreatment of patients with high-intermediate risk endometrial ...

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...